Cargando…

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells

Imatinib mesylate is the leading compound to treat chronic myeloid leukemia (CML) and other cancers, through its inhibition of Bcr-Abl tyrosine kinases. However, resistance to imatinib develops frequently, particularly in late-stage disease and has necessitated the development of new Bcr-Abl inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Arvaniti, Katerina, Papadioti, Anastasia, Kinigopoulou, Maria, Theodorou, Vassiliki, Skobridis, Konstantinos, Tsiotis, Georgios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302748/
https://www.ncbi.nlm.nih.gov/pubmed/28250386
http://dx.doi.org/10.3390/proteomes2030363
_version_ 1782506604858441728
author Arvaniti, Katerina
Papadioti, Anastasia
Kinigopoulou, Maria
Theodorou, Vassiliki
Skobridis, Konstantinos
Tsiotis, Georgios
author_facet Arvaniti, Katerina
Papadioti, Anastasia
Kinigopoulou, Maria
Theodorou, Vassiliki
Skobridis, Konstantinos
Tsiotis, Georgios
author_sort Arvaniti, Katerina
collection PubMed
description Imatinib mesylate is the leading compound to treat chronic myeloid leukemia (CML) and other cancers, through its inhibition of Bcr-Abl tyrosine kinases. However, resistance to imatinib develops frequently, particularly in late-stage disease and has necessitated the development of new Bcr-Abl inhibitors. The synthesis of a new series of phenylaminopyrimidines, structurally related to imatinib, showed large interest since the introduction of nilotinib. Here, we compare the protein levels in K562 cells treated with either imatinib or with novel imatinib derivates. Our results revealed that among the 986 quantified proteins, 35 had significantly altered levels of expression by imatinib or its derivates. In a second series of experiments, we directly compared the proteomes of imatinib treated K562 cells with those K562 cells treated with any of the four imatinib derivates. More than 1029 protein were quantified, 80 of which had altered levels of expression. Both experiments pointed to changes in the expression of the ATP-dependent RNA helicase DDX3X and of two mitochondrial coiled-coil-helix-coiled-coil-helix domain-containing proteins.
format Online
Article
Text
id pubmed-5302748
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-53027482017-02-27 Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells Arvaniti, Katerina Papadioti, Anastasia Kinigopoulou, Maria Theodorou, Vassiliki Skobridis, Konstantinos Tsiotis, Georgios Proteomes Article Imatinib mesylate is the leading compound to treat chronic myeloid leukemia (CML) and other cancers, through its inhibition of Bcr-Abl tyrosine kinases. However, resistance to imatinib develops frequently, particularly in late-stage disease and has necessitated the development of new Bcr-Abl inhibitors. The synthesis of a new series of phenylaminopyrimidines, structurally related to imatinib, showed large interest since the introduction of nilotinib. Here, we compare the protein levels in K562 cells treated with either imatinib or with novel imatinib derivates. Our results revealed that among the 986 quantified proteins, 35 had significantly altered levels of expression by imatinib or its derivates. In a second series of experiments, we directly compared the proteomes of imatinib treated K562 cells with those K562 cells treated with any of the four imatinib derivates. More than 1029 protein were quantified, 80 of which had altered levels of expression. Both experiments pointed to changes in the expression of the ATP-dependent RNA helicase DDX3X and of two mitochondrial coiled-coil-helix-coiled-coil-helix domain-containing proteins. MDPI 2014-07-22 /pmc/articles/PMC5302748/ /pubmed/28250386 http://dx.doi.org/10.3390/proteomes2030363 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Arvaniti, Katerina
Papadioti, Anastasia
Kinigopoulou, Maria
Theodorou, Vassiliki
Skobridis, Konstantinos
Tsiotis, Georgios
Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
title Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
title_full Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
title_fullStr Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
title_full_unstemmed Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
title_short Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
title_sort proteome changes induced by imatinib and novel imatinib derivatives in k562 human chronic myeloid leukemia cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302748/
https://www.ncbi.nlm.nih.gov/pubmed/28250386
http://dx.doi.org/10.3390/proteomes2030363
work_keys_str_mv AT arvanitikaterina proteomechangesinducedbyimatinibandnovelimatinibderivativesink562humanchronicmyeloidleukemiacells
AT papadiotianastasia proteomechangesinducedbyimatinibandnovelimatinibderivativesink562humanchronicmyeloidleukemiacells
AT kinigopouloumaria proteomechangesinducedbyimatinibandnovelimatinibderivativesink562humanchronicmyeloidleukemiacells
AT theodorouvassiliki proteomechangesinducedbyimatinibandnovelimatinibderivativesink562humanchronicmyeloidleukemiacells
AT skobridiskonstantinos proteomechangesinducedbyimatinibandnovelimatinibderivativesink562humanchronicmyeloidleukemiacells
AT tsiotisgeorgios proteomechangesinducedbyimatinibandnovelimatinibderivativesink562humanchronicmyeloidleukemiacells